| Literature DB >> 31138107 |
Poomarin Phloyphisut1, Natapol Pornputtapong2,3, Sira Sriswasdi4,5, Ekapol Chuangsuwanich6,7,8.
Abstract
BACKGROUND: Immunotherapy is an emerging approach in cancer treatment that activates the host immune system to destroy cancer cells expressing unique peptide signatures (neoepitopes). Administrations of cancer-specific neoepitopes in the form of synthetic peptide vaccine have been proven effective in both mouse models and human patients. Because only a tiny fraction of cancer-specific neoepitopes actually elicits immune response, selection of potent, immunogenic neoepitopes remains a challenging step in cancer vaccine development. A basic approach for immunogenicity prediction is based on the premise that effective neoepitope should bind with the Major Histocompatibility Complex (MHC) with high affinity.Entities:
Keywords: Deep learning; MHC epitope prediction; Recurrent neural networks
Mesh:
Substances:
Year: 2019 PMID: 31138107 PMCID: PMC6540523 DOI: 10.1186/s12859-019-2892-4
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Fig. 1An overview of the MHCSeqNet’s architecture. The model is comprised of three main parts: the peptide sequence processing part (a & c), the MHC processing part (b & d), and the main processing part which accepts the processed information from the previous parts (e). The entire model is a single deep learning model which can be trained altogether. f Our models output binding probability for the given peptide and MHC allele on the scale of 0 to 1, with 1 indicating likely ligand
Fig. 2MHCSeqNet achieves the best AUC and F1 scores on MHC class I binding dataset. a Bar plots showing the AUC value of each tool when evaluated on the set of MHC alleles it supports (Supported Type) or on the set of MHC alleles supported by all tools (Common Type). b Similar bar plots showing F1 values. c The ROC plot for all tools when evaluated on the set of MHC alleles supported by all tools. Vertical black line indicates the 5% false discovery rate (FDR). Inset shows the zoomed in ROC plot for the region with ≤5% FDR. d Similar ROC plot for the evaluation on MHC alleles supported by individual tools
Typed MHC alleles of four individuals in the MHC class I ligand peptidome dataset
| Sample ID | Mel 12 | Mel 15 | Mel 16 | Mel 8 |
|---|---|---|---|---|
| HLA-A | A*01:01 | A*03:01 | A*01:01 | A*01:01 |
| - | A*68:01 | A*24:02 | A*03:01 | |
| HLA-B | B*08:01 | B*27:05 | B*07:02 | B*07:02 |
| - | B*35:03 | B*08:01 | B*08:01 | |
| HLA-C | C*07:01a | C*02:02b | C*07:01a | C*07:01a |
| - | C*04:01 | C*07:02 | C*07:01a |
aAlleles not supported by the original MHCflurry
bAllele supported by only our sequence-based model
Fig. 3MHCSeqNet achieves the best AUC and F1 scores on MHC class I ligand peptidome dataset. a The ROC plot for all tools. Vertical black line indicates the 5% FDR. Inset show the zoomed in ROC plot for the region with ≤5% FDR. b Bar plots showing the AUC (bars with solid face colors) and F1 (bars with stripes) scores of each tool